Currently trading at PENNIES, this NASDAQ company has TWO FDA approved offerings

[View online]( [UNSUBSCRIBE]( NEW ALERT: ** NASDAQ: JAGX ** Currently trading at PENNIES, this NASDAQ company has TWO FDA approved offerings that could help millions of human beings and dogs from suffering… Greetings All, The pharma space includes many companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. These products must go through rigorous, costly, and time-consuming trials before potentially obtaining approval from the FDA. One emerging company trading on the NASDAQ at only PENNIES, has already has a commercialized FDA-been approved drug product for humans and a commercialized FDA conditionally approved drug product for dogsby the FDA twice! There is a reason why pharma companies get a lot of attention on Wall Street. This is because they see significant revenue streams once their drugs see success commercially. Jaguar Health, Inc. (NASDAQ: JAGX) is identifying opportunities to develop and commercialize first-in-class, plant-based prescription medicines… Included in their pipeline is a product suite is a proprietary plant-based drug approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy AND a product that is the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA! Crofelemer, the The first-in-class active ingredient in both drugs, is also being evaluated for looked at to treatment of prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Crofelemer This is already in a pPhase 3 clinical trial for this proposed indication! Annual revenues in for the pharmaceutical industry as a whole top $1T a year, and with the population in many key markets ageing, that number looks set to grow even further. Jaguar Health, Inc. (NASDAQ: JAGX) has an exciting plant-based medicinal pipeline and a story that seems to be ready to quickly start moving forward…. [( NASDAQ: JAGX From TREE to BOTTLE, the Company is committed to discovering, developing, and commercializing plant-based prescription medicines for urgent global health needs! Jaguar Health, Inc. (NASDAQ: JAGX) focuses on developing novel, sustainably derived gastrointestinal products on a global basis. The company is committed to identifying opportunities to develop and commercialize first-in-class, plant-based prescription medicines that leverage their broad intellectual property portfolio, deep pipeline, and extensive botanical library and address unmet medical needs for people around the globe. JAGX Their wholly owned subsidiary, Napo Pharmaceuticals (Napo), focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Napo Therapeutics, the Italian corporation established by Jaguar in Milan, Italy in 2021, focuses on expanding crofelemer access in Europe. Jaguar is the majority shareholder of Napo Therapeutics, and Napo Therapeutics’ mission is to provide access to Jaguar's plant-based medicine crofelemer in Europe to address such significant rare disease indications. Under its license to crofelemer from Jaguar, Napo Therapeutics’ initial focus is on clinical development and future registration in Europe of crofelemer for debilitating orphan disease target indications, starting with short bowel syndrome (SBS) and congenital diarrheal disorders (CDD). Jaguar anticipates the completion in 2022 of a third-party, investigator-initiated proof-of-concept study of crofelemer for SBS, supporting the potential for reimbursed expanded patient access through programs in Europe in 2023 for this devastating and catastrophic disease. The third-party investigator is targeting the presentation in December 2022 of results from this SBS study at a global GI conference in Dubai. At JAGX and Napo Therapeutics, they recognize the unique and powerful knowledge traditional peoples have about plants, ecosystems, interrelationships, and healing compounds. This knowledge has led to drug products that have changed the world. The two companies prioritize IP protection and the Company currently holds approximately 147 patents and approximately 37 patents pending! Products and Pipeline Mytesi® - the [ONLY FDA-approved]( diarrhea treatment that's been studied specifically in adults with HIV/AIDS!  About Mytesi® Mytesi® (crofelemer), a product of Jaguar’s wholly -owned subsidiary Napo Pharmaceuticals, is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Mytesi Crofelemer is a novel, first‑in‑class anti‑secretory agent which has a basic normalizing effect locally oin the gut, and this mechanism of action has the potential to benefit multiple gastrointestinal disorders. JAGX, through Napo, holds extensive and exclusive global rights! for Mytesi and estimates the U.S. market revenue potential for Mytesi® to be [~$50-70 mm in gross annual sales!]( Mytesi is in development for multiple possible follow‑on indications, including diarrhea related to targeted cancer therapy; orphan‑drug indications for infants and children with congenital diarrheal disorders (CDDs) and short bowel syndrome (SBS); supportive care for inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); and for idiopathic/functional diarrhea. In addition, a second‑generation proprietary anti‑secretory agent is in development for the symptomatic relief of diarrhea from cholera. Mytesi is the result of decades of research that began with the expertise of traditional healers of the Amazon Rainforest. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rrainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity. Crofelemer is currently the subject of the company's [OnTargetÂ]( an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar expects enrollment in this pivotal trial to complete in the first half of 2023. The United States Patent and Trademark Office on July 19, 2022 [issued a new U.S. patent]( to the CompanyNapo Pharmaceuticals (Napo) for methods for treating diarrhea, as well as the pain, abdominal discomfort and other symptoms associated with diarrhea, in patients with an inhibitor of chloride-ion transport such as Napo's crofelemer drug product. About Cancer Therapy-related Diarrhea A significant proportion of patients undergoing cancer therapy experience diarrhea, and diarrhea has the potential to cause dehydration, potential infections, and non-adherence to treatment in this population. Novel "targeted cancer therapy" agents, such as epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors (TKIs), with or without cycle chemotherapy agents, may cause increased electrolyte and fluid content in the gut lumen, which results in passage of loose/watery stools (i.e., diarrhea). Diarrhea has been reported as one of the most common side effects of TKIs and may result in cancer therapy drug holidays or reductions from therapeutic dose, potentially impacting patient outcome. Diarrhea is also a common side effect of some approved CDK 4/6 inhibitors. It doesn’t end with humans…. This company is focusing on our beloved furry companions too using the power of cCrofelemer! Canalevia®-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA! THIS IS A NEW STANDARD OF CARE FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED DIARRHEA (CID) IN DOGS. WHAT IS Canalevia-CA1? Canalevia-CA1 normalizes fluid flow to reinstate normal function in the GI tract and is an antidiarrheal, enteric-coated tablet for oral administration. It acts locally and it is not absorbed into the blood stream, resulting in a well- tolerated and non-opioid drug product. ​ It is naturally and sustainably harvested from the sap of a medicinal tropical plant, the Croton lechleri tree. “Diarrhea is a common side effect of chemotherapy in dogs, which can be so severe that cancer treatment must be halted. Chemotherapy drugs often have potential side effects, but, unlike in human medicine where patients may be willing to tolerate some discomfort in exchange for a potential cure, the primary purpose of cancer treatment in dogs and other pets is to extend survival without sacrificing quality of life and comfort. This new medication provides veterinarians and dog owners with another tool to help control the side effects of chemotherapy for dogs undergoing such treatment.” Steven M. Solomon, D.V.M., M.P.H., director of the FDA’s Center for Veterinary Medicine - [FDA News Release]( [December 21, 2021 "FDA Conditionally Approves First Oral Tablet to Treat Chemotherapy-Induced Diarrhea in Dogs"]( Canalevia-CA1 is well tolerated with only a three-day course of treatment for dogs under 140 lbs.! 2. Canalevia®-CA1 [package insert]. San Francisco, CA: Jaguar Animal Health, Inc; March 2022. JAGX has excitingly entered [an exclusive license and services agreement]( with Ontario, Canada-based SynWorld Technologies Corporation (SynWorld) for the treatment of diarrhea in dogs in the massive China market with Jaguar's Canalevia® (crofelemer delayed-release tablets) prescription drug product. "We are very excited about the possibility of making Canalevia available in China as part of the license we have provided to SynWorld for crofelemer for treatment of diarrhea in dogs in this territory. Per the terms of the agreement, Jaguar is engaging SynWorld as a service provider to obtain regulatory approval of the product for Jaguar in China and granting SynWorld a license to commercialize and sell this product following such approval in China. As consideration for the license, Jaguar is entitled to receive 60% of any profits from sales of the product in China. If Jaguar reimburses SynWorld for the direct expense of obtaining regulatory approval in China, the profit sharing will be 80% and 20%, respectively, for Jaguar and SynWorld." Lisa Conte, Jaguar's founder, president, and CEO. JAGX also has an ongoing relationship with[Quadri Pharmaceuticals Store LLC (Quadri Pharma)]( following the execution on March 31, 2022 of an exclusive crofelemer distribution and license agreement with Quadri Pharma for multiple target indications in Middle East markets. JAGX recently released Gallup's analysis of results from [Take Charge of Canine Cancer]( the first-ever nationally representative survey of U.S. dog owners' experiences with the disease. The survey found that of the 67% of Americans who have had at least one dog in the past 10 years, nearly one in five - equating to approximately 30 million people - say at least one of their dogs has experienced cancer. Canine cancer is a major stressor for dog owners. Nearly one-third of survey respondents (29%) report it had a heavily negative impact on their quality of life, while 63% report feeling a lot of stress and 58% report feeling down and depressed a great deal during the experience. A [Gallup survey]( also found that the incidence - the percent of U.S. dogs newly diagnosed with cancer in 2021 - was 2.8 percent, which is approximately five times the 0.57 percent incidence of newly diagnosed cancer in humans that year. Canalevia-CA1 is well tolerated with only a three-day course of treatment for dogs under 140 lbs.! 2. Canalevia®-CA1 [package insert]. San Francisco, CA: Jaguar Animal Health, Inc; March 2022. JAGX has additionally established the Take C.H.A.R.G.E. Registry and Cancer Care Index to not only provide data on the incidence and prevalence of canine cancer to drive treatment advances, but also to drive improvement across three fundamental dimensions of the treatment experience: knowledge and awareness, quality of care, and a dog's comfort. Take C.H.A.R.G.E. This is a first-of-its-kind national Canine Cancer Registry and Canine Cancer Care Index to provide the veterinary community and dog owners with important incidence and prevalence data to help guide canine cancer diagnosis and treatment decisions. Mental Health Initiative In September 2020, JAGX launched the Entheogen Therapeutics Initiative (ETI) to support the discovery and development of novel, plant-based medicines derived from psychoactive plants for treatment of mood disorders, neuro-degenerative diseases, addiction, and other mental health disorders. The Growing Market for Medicines Derived from Psychoactive Plants According to the World Health Organization, one in four people in the world will be affected by mental or neurological disorders at some point in their lives. Around 450 million people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health and disability worldwide. ([SOURCE]( The Bottom Line JAGX’s library of approximately 2,300 medicinal plants from tropical regions comprises a unique asset to drive drug discovery… With the expectation that proof-of-concept data for crofelemer for the orphan indications of short bowel syndrome (SBS) and potentially congenital diarrheal disorders (CDD) may be available this year, and the Company’s expectation that enrollment will complete in the first half of 2023 for the Phase 3 OnTarget trial of crofelemer for the treatment of prophylaxis of diarrhea in adult cancer patients receiving targeted therapy, it's an exciting time to be watching JAGX. Not one, but TWO FDA approved commercialized drugs offerings makes Jaguar Health, Inc. (NASDAQ: JAGX) an exciting growth story to pay attention to.. Trading at just PENNIES, this pharma company is already in the commercial stage and the revenue potential looks massive! Start your research right away!       Copyright 2022 © TopStockTips is owned and operated by Top Stock Tips Ltd. [Disclaimer and PrivacyÂ]( more Information please contact editor@topstocktips.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. This communication includes advertising material and PAID ADVERTISEMENTS provided to our subscribers. Copyright 2022 © TopStockTips.com is 50% owned and operated by the owner of CareBear Marketing Group LLC. Disclaimer and Privacy For more Information please contact Support@TopStockTips.com Company Address: 26 Downing Street, Newark NJ 07105. This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.  CareBear Marketing Group, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to TST. TST is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly.  Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by CareBear Marketing Group. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “TST” refers to CareBear Marketing Group. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in JAGX. We have been currently compensated up to Seventy Five Thousand Dollars Cash ($75,000) via bank wire transfer from a third-party Legenda Media for a 2 Day Marketing Program regarding JAGX with a start date of 8/23/2022 to 8/25/2022. TST’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TST often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. , Rua Frei Tome de Jesus N18 1Dto, 1700-215, Lisboa, Portugal You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](